A Phase 2/3 Randomized Open-Label Study of Toca 511 a Retroviral Replicating Vector Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)
Brief description of study
If you have been diagnosed with glioblastoma or anaplastic astrocytoma, types of brain tumors, you may qualify for this phase 2/3 study. The main goal of this study is to determine if the investigational products, Toca 511 and Toca FC, as a combination treatment is effective (works) and safe, compared to a selected number of approved treatments for brain tumors, called a control treatment.
Clinical Study Identifier: s15-00205
ClinicalTrials.gov Identifier: NCTs15-00205
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
